Cysteinylglycine or -glutamylcysteine have been proposed as possible alternatives.In a trial of adolescents with poorly controlled type 1 diabetes, a dose of 30-45mg/kg/day NAC failed to correct several markers of glutathione status, suggesting either a higher dose or alternative therapies may be indicated in this population.A recent study of patients with poorly controlled type 2 diabetes found that dietary supplementation of the amino acids cysteine and glycine, markers of glutathione synthesis and plasma oxidative stress were both improved
GLP-1RA therapy inhibits glucagon secretion, at least transiently delays gastric emptying, and reduces appetite and food intake [60,61]
Because of this rapid degradation, it was widely believed that oral glutathione had extremely poor bioavailability (often estimated at less than 5%) and could not effectively raise systemic intracellular stores
Many people prescribed GLP-1s for weight loss report GI side effects and a drastically reduced appetite, which can make it incredibly difficult to eat enough to meet basic needs let alone thrive
Rarely, unless combined with insulin or sulfonylureas